The U.S. Food and Drug Administration (FDA) announced a new process called “Rare Disease Evidence Principles” (RDEP), under which eligible drugs and biologics for ultra-rare diseases caused by known ...

The U.S. Food and Drug Administration is actively steering drug developers away from traditional animal studies and toward human-biology-based testing methods for monoclonal antibody programs. The ...

The Food and Drug Administration (FDA) development and approval process for drugs and medical devices involves multiple phases that ensure the safety and effectiveness of products before and after ...

Scientists at the University of Cambridge have developed a new way to alter complex drug molecules using light rather than ...

March 18 (Reuters) - The U.S. Food and Drug Administration on Wednesday issued a draft guidance to help companies reduce animal studies of experimental drugs and adopt newer methods, such as computer ...

SAN FRANCISCO, Jan 26 (Reuters) - Artificial intelligence has yet to deliver on the most challenging aspect of drug development -- finding new molecules that lead to major medical advances -- but it ...

Animal studies often fail to predict human tissue responses to new drugs or newly developed therapies. Besides generating tremendous costs for clinical studies, it also raises significant ethical ...

The U.S. Senate has a plan to improve drug development for rare disease patients. The exit of controversial CBER chief Vinay Prasad will help clear the path.

“There are over 600,000 drugs in the Korea Chemical Bank alone. It felt overwhelming to find a drug that perfectly fits the protein structure we’re targeting among them. That’s when I thought of AI ...

While on Galapagos, Darwin noticed that the giant tortoises, mockingbirds, and finches he studied differed in unique ways from the species that inhabited neighboring islands. It’s been almost 200 ...